| Literature DB >> 35242802 |
Kuo Chen1, Narasimha M Beeraka2,3, Mikhail Y Sinelnikov2, Jin Zhang2, Dajiang Song4, Yuanting Gu1, Jingruo Li1, I V Reshetov2,5,6, O I Startseva2, Junqi Liu7, Ruitai Fan7, Pengwei Lu1.
Abstract
BACKGROUND ANDEntities:
Keywords: DIEP flap; breast reconstruction; intraoperative; patient management; perioperative; postoperative period; surgery
Year: 2022 PMID: 35242802 PMCID: PMC8887567 DOI: 10.3389/fsurg.2022.729181
Source DB: PubMed Journal: Front Surg ISSN: 2296-875X
Figure 1Depiction of exclusion and inclusion criteria of patients who were undergone breast reconstruction and total 106 papers were primarily screened with respect to actuality, publication date, access to article text, content, number of patients, and complete flap-loss rate. Primary screening was executed and selected 56 research papers for secondary screening. Consequently, a two-stage screening process was performed and selected 21 research papers for this study.
Figure 2Three main groups were chosen for proper categorization for further inferences to delineate the efficient patient management in preoperative period during DIEP flap-based breast reconstruction. This categorization was performed according to the preoperative preparation, postoperative patient management, and choice of the intraoperative therapy.
The patient management strategies in preoperative, intraoperaitve, and postoperative periods in order to minimize different complications observed in the DIEP flap-based breast reconstruction.
| Modifiable risk factors | Diagnosis of modifiable risk factors, such as smoking, obesity, pharmacological therapy, hypertension and their correction. |
| Preoperative visualization | Rainbow 3D DIS, MSCT with angiography, Static CT-scanning, flap volume planning (calculation), perfusion zone analysis, choke-anastomosis analysis, Doppler ultrasound of recipient vessels. |
| Patient history | Obstetric history (previous births), scarring on the chest/abdomen, hernia formation data, operative intervention history, prior radiation, and chemotherapy, risk factor analysis. |
| Analgesic therapy | Preoperative administration of Gabapentin decreases pain and vomit postoperatively. |
| Patient body temperature | Mean body temperature should be maintained at 37°C intraoperatively |
| Anesthesia | Secondary epidural anesthesia decreases postoperative complication incidence. |
| Infusion | Crystalloid infusion should be 3.5–6 ml/kg/h in the nearest postoperative period (24 h). |
| Spasmolytics | Persistent vasospasm can be corrected with topical administration of 4% lidocaine or papaverine. |
| Vasopressors | Vasopressors are used to correct hypotensive conditions, and do not increase the complication rate. |
| Anticoagulation therapy | Aspirin and subcutaneous heparin administration are recommended for thrombotic complication prophylaxis. |
| Analgesic | Anesthetic pump in the donor area significantly reduces pain in the postoperative period. |
| Surgical technique | Venous superdrainage is a recommended operative technique. |
| Perfusion control | USDG (Doppler ultrasound), DIRP, T.Ox Tissue Oximeter. |
Different clinical reports of overall complication rate (light/medium/severe) in the patient management in the DIEP flap-based breast reconstruction.
|
|
|
|
|
|
|
| |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
| ||||
|
| |||||||||||||
| Nahabedian et al. ( | Patient weight assessed prior to surgery, flap volume assessed and estimated, Rainbow 3D Digital Imaging System utilized. | 20 | 0% | 0% | 5% | 10% | NA | 0% | 15% | NA | 5% | NA | 5% |
| Gill et al. ( | Risk factors are assessed. Risk factors are modified prior to surgery: smoking, hypertension, radiation therapy. Radiation therapy after a mastectomy is avoided. | 758 | 12.9% | 4.3% | 20.2% | 0.7% | 2.5% | 14.3% | 5.9% | NA | 0.5% | 5.9% | 7.46% |
| Minqiang et al. ( | MSCT-angiography and preoperative imaging are performed and show effective reduction in postoperative complication rate. | 22 | 5% | NA | 0% | 0% | 1.6% | ||||||
| Santanelli et al. ( | Obstetric anamnesis (number of births) is assessed. It is proved to be a significant factor in perfusion related complications of the flap. | 287 | 12.9% | NA | NA | SM | NA | NA | SM | SM | NA | 6.9% | |
| Guerra et al. ( | Risk factors and other criteria are noted to be precursors of complication development: smoking, obesity, age, radiation therapy, flap volume | 280 | 12.5% | 2.5% | NA | 1.1% | 2.1% | 1.1% | SM | NA | 6.4% | 4.28% | |
| O'Connor et al. ( | Preoperative markup with prior quality vessel visualization is performed via dynamic CT visualization and/or static CT-scanning. Adequate preoperative markup allows for best flap volume transfer results. | 632 | 6.9% | 0.9% | 0.31% | Consistent with findings of other authors | NA | 2.52% | |||||
| Ooi et al. ( | Preoperative planning of flap volume is performed. The incidence of postoperative complications is significantly less in cases of preoperative assessment of flap perfusion zones. | Review of 5 different cohort | Consistent data with findings of other papers - author's statement. | NA | 0.75% | NA | est. 4% | ||||||
| Parrett et al. ( | Preoperative scar tissue is assessed and marked. It is necessary to understand donor site scarring and its role in flap perfusion. Scar tissue is excluded from the flap. | 104 | 14% | NA | 12% | NA | 1% | 5.1% | 10.2% | NA | 2.9% | NA | 8.02% |
|
| |||||||||||||
| Bonde et al. ( | Fast track surgery and reduction of LOS (length of hospital stay). Perioperative patient management. Less operative time correlates with less post-anesthesia consequences, less blood-loss and better results overall. | 177 | 6.5% | 9% | NA | 2% | NA | 5.83% | |||||
| Enajat et al. ( | Perform two venous anastomoses instead of one. This provides a lesser incidence of venous and perfusion complications, which provides better operative results. | 291 | SM | 0% | SM | Similar results | SM | 0% | SM | 7.8% | |||
| Andree et al. ( | Fibrin glue is used. This allowed for a reduction in overall complication rate and minimization of complete flap loss. | 201 | NA | 0.9% | SM | NA | |||||||
| Lemaine et al. ( | Heparin therapy by low-molecular weight heparin is performed to assess intraoperative vascular thrombosis risk. Anticoagulation therapy is recommended to oncologic patients on life-time courses. | 56 | 0% | 3.4% | NA | NA | 1.7% | NA | 5.9% | 1.7% | 1.9% | 3.4% | 2.57% |
| Liu et al. ( | Temperature control. Hypothermia of 36,0-36,5C correlates with lower levels of microvascular complications. | 212 | Low flap thrombosis rate | NA | |||||||||
|
| |||||||||||||
| Chiu et al. ( | Gabapentin is used as a preoperative drug. Postoperatively correlated with less pain. Pain management is performed. | 25 | Postoperative pain management. | NA | |||||||||
| Zhong et al. ( | Infusion control. Optimal levels of crystalloid infusion are 3.5ml-6ml/kg per hour to replenish lost fluids. | 354 | 4.2% | 7.3% | NA | 0.8% | NA | 4.1% | |||||
| Khouri et al. ( | Subcutaneous heparin was administered postoperatively. Less risk of microvascular thrombosis was noted. | 493 | NA | 8.3% | NA | NA | NA | NA | 2.7% | NA | 4.1% | 9.9% | 6.25% |
| Eley et al. ( | Vasopressor use. It is not recommended to administer vasopressors prior to dissection. Vasopressor administration after flap mobilization did not impact perfusion quality. It is not recommended to use epinephrine and dopexamine, as they correlate with a higher complication rate. Vasopressors are recommended postoperatively to improve overall perfusion quality | 24 | Perfusion change assessment with clinical application. | NA | |||||||||
| (combined with intravenous infusion). | |||||||||||||
| Enajat et al. ( | Anticoagulant regiments evaluated. In total 325 mg of aspirin per os every 24 h or 5000 ME of LMW heparin subcutaneously every 24 h are methods of choice. | 592 | NA | 3.4% | NA | NA | 5.4% | NA | 9.2% | NA | 2.8% | 2.6% | 4.68% |
| Harris et al. ( | Vasopressor use assessed. Dobutamin with norepinephrine combined therapy show positive effects in flap perfusion quality. | 496 | SM | 5.2% | NA | NA | 1.4% | SM | 1.6% | NA | 2.2% | NA | 4.66% |
| Riva et al. ( | Anithrombotic therapy regimens evaluated. Dextran is contraindicated and is harmful to postoperative flap stability. Increases complication rate. Antithrombotic therapy with dextran and/or PGE1 did not impact flap viability. | 1,351 | Pharmacological antithrombotic agent assessment. | NA | |||||||||